Investigating Live Attenuated Influenza Vaccine Efficacy in Senegal

This fact sheet describes a phase 3 clinical study that PATH and our partners are conducting in Senegal to evaluate the clinical efficacy of a seasonal, trivalent live attenuated influenza vaccine (LAIV). By providing evidence on how well this type of vaccine works among young children in Senegal, this study will help inform efforts in the scientific community to develop optimal LAIVs for the world’s most vulnerable children, as well as policy decisions for potential future LAIV use in Senegal and other tropical, low-resource countries in Africa.

Publication date: May 2013

Available materials

  1. English

    1. Investigating Live Attenuated Influenza Vaccine Efficacy in Senegal 119.8 KB PDF
  2. French

    1. Investigating Live Attenuated Influenza Vaccine Efficacy in Senegal [French] 120.5 KB PDF